Meningococcal vaccine groups A C Y W-135 conjugate - sanofi pasteur

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - sanofi pasteur

Alternative Names: MCV-4; Menactra; Menactra Infant/Toddler; Menactra Toddler; Meningo ACWY; Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine; Meningococcal polysaccharide diphtheria toxoid conjugate vaccine; SP284

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi pasteur
  • Developer Novartis Vaccines; Sanofi Pasteur
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 19 Aug 2016 Launched for Meningococcal infections (Prevention) in South Korea (IM) prior to August 2016
  • 19 Aug 2016 Registered for Meningococcal infections (Prevention) in South Korea (IM) prior to August 2016
  • 01 Jun 2016 Phase-II clinical trials in Meningococcal infections (In infants, In children, In adolescents, In adults, Prevention) in Vietnam (IM) (NCT02640404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top